

AD _____

Award Number: W81XWH-04-1-0789

TITLE: Critical Importance of Protein 4.1 in Centrosome and Mitiotic Spindle
Aberrations in Breast Cancer Pathogenesis

PRINCIPAL INVESTIGATOR: Sharon W. Krauss

CONTRACTING ORGANIZATION: Lawrence Berkeley National Laboratory
Berkeley, CA 94720

REPORT DATE: September 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060428783

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-09-2005		2. REPORT TYPE Annual		3. DATES COVERED 1 Sep 2004 – 31 Aug 2005	
4. TITLE AND SUBTITLE Critical Importance of Protein 4.1 in Centrosome and Mitotic Spindle Aberrations in Breast Cancer Pathogenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0789	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sharon W. Krauss				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Lawrence Berkeley National Laboratory Berkeley, CA 94720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT – SEE ATTACHED PAGE					
15. SUBJECT TERMS Breast Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)
			UU	5	

Abstract

Important pathological hallmarks of many breast cancers include centrosome amplification, spindle pole defects leading to aberrant chromosome segregation, altered nucleoskeletal proteins and perturbed cytokinesis. Our recent data showing that protein 4.1 is crucial for proper centrosome, spindle and nuclear assembly/maintenance led us to hypothesize that protein 4.1 is involved in centrosome dynamics, fidelity of cell division and cell cycle progression.

To decipher 4.1 functions in breast cancer, we studied the detailed distribution of two 4.1 family members, 4.1R and 4.1G and found that protein 4.1 R and 4.1G localize differentially within centrosomes and spindles and behave differently during the cell cycle. In several breast cancer cell lines with normal centrosome numbers, we determined that 4.1R localizes to one or both centrioles in randomly growing populations. By contrast, in other breast cancer cell lines with amplified centrosomes we detected 4.1R at a subset of hyperamplified centrioles. We are currently investigating 4.1 distribution in other breast cancer cell lines and assessing changes after specific 4.1 downregulation by RNAi. Our ultimate aim is to determine if 4.1 or its binding partners could be important chemotherapeutic targets in breast cancer treatment.

Table of Contents

Cover.....	1
SF 298.....	2
Abstract	3
Table of Contents.....	4
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	
Reportable Outcomes.....	
Conclusions.....	5
References.....	none
Appendices.....	none

Important pathological hallmarks of many breast cancers include centrosome amplification, spindle pole defects leading to aberrant chromosome segregation, altered nucleoskeletal proteins and perturbed cytokinesis. Previously we established in human cells that protein 4.1, initially described as a human red cell skeletal protein, is also a component of centrosomes, mitotic spindles, nuclear skeleton and the midbody at cytokinesis. Importantly we recently showed by depletion/add back experiments that protein 4.1 itself is crucial for proper centrosome, spindle and nuclear assembly and that dominant/negative 4.1 peptides added to cell extracts produced multipolar and asymmetric mitotic spindles and disrupted microtubule organization necessary to assemble and maintain centrosomes. Taken together, these data lead us to hypothesize that protein 4.1 is involved in centrosome dynamics, the fidelity of cell division and in cell cycle progression.

Protein 4.1 is now known to be a multigene family. We are investigating roles of two family members, 4.1R (red cell) and 4.1G (generally expressed) in centrosome amplification and mitotic spindle aberrations in breast cancer pathogenesis. Centrosomes are composed of a cylindrical centriole pair surrounded by a larger fibrogranular area, the pericentriolar material (PCM). The more mature (or mother) centriole has "appendages" at its distal end that appear to anchor cytoplasmic microtubules. Centrosomes duplicate to become mitotic spindle poles for partitioning chromosomes.

In order to decipher 4.1 functions in breast cancer, we studied the detailed distribution of 4.1R and 4.1G at centrosomes. We report here that, by immunofluorescent microscopy, protein 4.1 R and 4.1G localize differentially within centrosomes. Protein 4.1R surrounds the centriolar "barrel" while 4.1G localizes in the outlying PCM. In mitotic spindles 4.1R is again associated with centrioles while 4.1G is distributed in the spindle matrix. Moreover, we observed that 4.1R is specifically associated with the mature (or mother) centriole, coincident with mature centriole marker proteins ninein and p150/glued by immunofluorescent microscopy. During cell cycling, 4.1R is at one centriole but spreads to the maturing daughter centriole during S phase, finally localizing during G2 at both mature centrioles after centriole duplication. Protein 4.1G epitopes remain in the PCM throughout the cell cycle. Applying these observations to breast cancer cell lines, we find that in breast cancer cell lines with normal centrosome numbers (MCF10A transformed cells and MCF7 tumor cells), protein 4.1R localizes to one or both centrioles in randomly growing populations. By contrast, in breast cancer cell lines with amplified centrosomes, such as MDAMB231 and T47D, 4.1R is observed at a subset of hyperamplified centrioles defined by centrin immunostaining. We are currently investigating 4.1R and 4.1G distribution in other breast cancer cell lines in preparation to assess changes in cellular phenotypes after specific downregulation of protein 4.1R and G. Our ultimate aim is to determine if 4.1 or its binding partners could be important chemotherapeutic targets in breast cancer treatment.